Evidence map›Paper›PMID 38783199›Full record

ArticleJournal of neurodevelopmental disorders2024

Rescue of impaired blood-brain barrier in tuberous sclerosis complex patient derived neurovascular unit.

Jacquelyn A Brown, Shannon L Faley, Monika Judge, Patricia Ward, Rebecca A Ihrie, Robert Carson, Laura Armstrong, Mustafa Sahin, John P Wikswo, Kevin C Ess and 1 more

Abstract read
In one paragraph

Article in Journal of neurodevelopmental disorders, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Jacquelyn A BrownDepartment of Physics and Astronomy, Vanderbilt University, Nashville, USA.
Shannon L FaleyDepartment of Physics and Astronomy, Vanderbilt University, Nashville, USA.
Monika JudgeDepartment of Physics and Astronomy, Vanderbilt University, Nashville, USA.
Patricia WardDepartment of Physics and Astronomy, Vanderbilt University, Nashville, USA.
Rebecca A IhrieDepartment of Cell & Developmental Biology, Vanderbilt University, Nashville, USA.
Robert CarsonDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, USA.
Laura ArmstrongDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, USA.
Mustafa SahinRosamund Stone Translational Neuroscience Center, Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, USA.
John P WikswoDepartment of Physics and Astronomy, Vanderbilt University, Nashville, USA.
Kevin C Ess *Neurological Surgery, Vanderbilt University Medical Center, Nashville, USA. kevin.ess@childrenscolorado.org.ORCID 0000-0002-3730-7351
M Diana Neely *Department of Pediatrics, Vanderbilt University Medical Center, Nashville, USA. diana.neely@vumc.org.

Funding

Vanderbilt Institute for Clinical and Translational Research (VICTR) -Identifying correlates of functional immunity in SARS-CoV-2 convalescent plasmaUL1TR002243 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Paul A. Harris, Wesley H Self · 2017 to 2026
$130.7M
Toward better characterization and clinical trial readiness for targeting neuropsychiatric manifestations in PTEN pathogenic variantsU54NS092090 · NINDS · BOSTON CHILDREN'S HOSPITAL · PI Joseph D. Buxbaum · 2014 to 2026
$20.1M
Overall: Eunice Kennedy Shriver Intellectual and Developmental Disabilities Research Center at VanderbiltP50HD103537 · NICHD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Jeffrey L Neul · 2020 to 2026
$10.3M
Drug development for tuberous sclerosis complex and other pediatric epileptogenic diseases using neurovascular and cardiac microphysiological modelsUH3TR002097 · NCATS · VANDERBILT UNIVERSITY · PI ESS, KEVIN C, NEELY, MAJA DIANA · 2019 to 2021
$4.6M
Identifying mTOR Dependent Periods During Brain DevelopmentR01NS118580 · NINDS · VANDERBILT UNIVERSITY · PI ESS, KEVIN C, IHRIE, REBECCA A · 2020 to 2024
$2.1M
NCATS NIH HHS UH3 TR002097NCATS NIH HHS UH3TR002097NCATS NIH HHS UL1 TR002243NCATS NIH HHS UL1TR002243NICHD NIH HHS P50 HD103537NINDS NIH HHS R01 NS118580NINDS NIH HHS R01NS118580NINDS NIH HHS U54 NS092090NINDS NIH HHS U54NS092090
6 · The paper itself

Abstract

backgroundTuberous sclerosis complex (TSC) is a multi-system genetic disease that causes benign tumors in the brain and other vital organs. The most debilitating symptoms result from involvement of the central nervous system and lead to a multitude of severe symptoms including seizures, intellectual disability, autism, and behavioral problems. TSC is caused by heterozygous mutations of either the TSC1 or TSC2 gene and dysregulation of mTOR kinase with its multifaceted downstream signaling alterations is central to disease pathogenesis. Although the neurological sequelae of the disease are well established, little is known about how these mutations might affect cellular components and the function of the blood-brain barrier (BBB).

methodsWe generated TSC disease-specific cell models of the BBB by leveraging human induced pluripotent stem cell and microfluidic cell culture technologies.

resultsUsing microphysiological systems, we demonstrate that a BBB generated from TSC2 heterozygous mutant cells shows increased permeability. This can be rescued by wild type astrocytes or by treatment with rapamycin, an mTOR kinase inhibitor.

conclusionOur results demonstrate the utility of microphysiological systems to study human neurological disorders and advance our knowledge of cell lineages contributing to TSC pathogenesis and informs future therapeutics.

Indexed as

Blood-Brain BarrierInduced Pluripotent Stem CellsTuberous SclerosisTuberous Sclerosis Complex 2 ProteinAstrocytesHumansSirolimusSirolimusTSC2 protein, humanTuberous Sclerosis Complex 2 ProteinAstrocytesBBBHuman stem cellsMicrofluidicsmTORRapamycinTissue chips

Identifiers

PMID38783199
PMCPMC11112784

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.